跳至主要内容
临床试验/NCT06427850
NCT06427850尚未招募不适用

Effect of Topical Tranexamic Acid on Postoperative Drainage in Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI-TLIF): A Randomized Controlled Trial

Thanawan Longsuwan0 个研究点目标入组 28 人开始时间: 2024年7月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
28
主要终点
postoperative drainage (mL)

研究概览

简要总结

The randomized controlled study which compare the efficacy outcomes (reducing blood loss and drainage output in patients) in patients undergoing single-level minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) and received topical tranexamic acid injection in the surgical site to those who received placebo injection.

详细描述

Detail : Randomization of Patients for intra-surgical site topical tranexamic acid injection

Objective : To compare the efficacy of topical tranexamic acid (TXA) injection into the surgical wound versus placebo injection in reducing blood loss and drainage output in patients undergoing single-level minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) surgery.

Methods:

Patient: Patients with degenerative spine conditions undergoing single-level MI-TLIF surgery, who received treatment at Ramathibodi Hospital and Chakri Naruebodindra Medical Institute from 2024 to 2027.

Randomization : Patients will be randomly by various block randomization (1:1) was performed using STATA 16.0 to ensure that the two groups were comparable in size and that the sequence of randomization was unpredictable.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
30 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 30-80 years old
  • Degenerative spine problems including spinal stenosis, disc degeneration, spondylolithesis that indicated for single level MI-TLIF

排除标准

  • Revision surgery
  • Patients who had high risk of complication from TXA
  • History of seizure, PE, DVT, thromboembolic episode
  • History of TXA allergy
  • Patients who had high risk for bleeding
  • U/D : CKD stage more than IIIb (GFR< 45 ml/min/1.73m2), hepatic disease, bleeding disorder
  • On anticoagulation drug or antiplatelet drug in 7 days before surgery
  • Abnormal coagulation profile (INR > 1.5) or CBC (platelet < 100000)

研究组 & 干预措施

Topical tranexamic acid (TXA) injection

Experimental

receive an injection of topical tranexamic acid (TXA) into the surgical site

干预措施: Tranexamic acid (Drug)

Placebo group

Placebo Comparator

receive an injection Normal saline into the surgical site

干预措施: Normal saline (Drug)

结局指标

主要结局

postoperative drainage (mL)

时间窗: 120 hours

Fluid drainage after operation

次要结局

  • duration of drain maintenance (day)(120 hours)
  • calculated total blood loss (mL)(120 hours)
  • intraoperative blood loss (mL)(Intraoperative time)
  • length of hospital stay (day)(120 hours)
  • complication of tranexamic acid (TXA) and surgery(%)(120 hours)

研究者

发起方
Thanawan Longsuwan
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Thanawan Longsuwan

Doctor

Ramathibodi Hospital

相似试验